Xenon Pharmaceuticals Inc.

XENE

Held by 14 specialist biotech funds

High Convergence

14 funds opened new positions. Next phase2 readout (XEN1101): Sep 2021. Short interest: 5.9% of float.

BiotechnologyCEO: Andrea DiFabioIPO: 2014Website ↗

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Catalysts

Phase 2Q4 2009XPF-001Dental PainNCT00954356

Primary: Total Pain Relief at 6 Hours Post Dose (TOTPAR 6) (6 hours post dose)Enrollment:61/61Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2010XPF-001Primary Erythromelalgia, Inherited ErythromelalgiaNCT01090622

Primary: Pain intensity difference (PID) in each treatment period based on an 11-point Pain Intensity-NRS (where 0 = No pain and 10 = worst pain you can imagine) (2 days)Enrollment:4/4Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2011XPF-002Postherpetic NeuralgiaNCT01195636

Primary: Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF) (3 weeks)Enrollment:70/70Sites: 24RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2012XPF-002Primary Erythromelalgia, Inherited ErythromelalgiaNCT01486446

Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 (14-21 Days)Enrollment:8/8Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2017XPF-005Acne VulgarisNCT02656043

Primary: Change from Baseline in acne lesion count (Week 12)Enrollment:213/213Sites: 20RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2021XEN1101Focal EpilepsyNCT03796962

Primary: Median Percent Change in Focal Seizure Frequency (From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56))Enrollment:325/325Sites: 95RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ2 2023XEN496Epilepsy, Epilepsy in Children, Epilepsy; SeizureNCT04639310

Phase 2Q3 2023XEN1101 10 mgMajor Depressive DisorderNCT05376150

Phase 3NegativeQ4 2023XEN496Epilepsy, Epilepsy in Children, Epilepsy; SeizureNCT04912856

Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) Related to Intervention (From Screening/Baseline through to 4 weeks post last dose)Enrollment:8/8Sites: 4NON_RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2026AzetukalnerFocal Onset SeizuresNCT05614063

Phase 3Q3 2026AzetukalnerMajor Depressive DisorderNCT06775379

PDUFAQ3 2026AzetukalnerFocal Onset Seizures

Phase 3Q4 2026XEN1101Focal Onset SeizuresNCT05716100

Phase 3Q1 2027AzetukalnerMajor Depressive DisorderNCT06922110

Phase 3Q2 2027XEN1101Primary Generalized Tonic-Clonic SeizuresNCT05667142

Phase 3Q2 2027AzetukalnerMajor Depressive DisorderNCT07076407

Phase 3Q2 2028AzetukalnerBipolar Disorder, Bipolar Depression, Bipolar I DisorderNCT07172516

Primary: Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6. (Baseline to Week 6)Enrollment:Target 400Sites: 28RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2029AzetukalnerBipolar Depression, Bipolar I Disorder, Bipolar DisorderNCT07217860

Phase 3Q2 2033XEN1101Focal Epilepsy, Tonic-Clonic SeizuresNCT05718817

Xenon Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research